bluuebunny/crossref_metadata_2025_split huggingface dataset:
400-P: Impact of Hypoglycemic Episodes (Hypos) on Type 1 Diabetes Mellitus (T1DM)
Authors: SULLIVAN EMMA D. , KEMP JESSALYN , PIERCY JAMES , HIGGINS VICTORIA 
Published: June 2019

Objective: Compare functionality of T1DM patients who do or do not experience hypos and compare across hypo severities and requirement for medical help.
Methods: Data were drawn from 2016 Adelphi Disease Specific Programme, a real-world, cross-sectional study in 5EU/U.S. Physicians completed forms for the next 2 T1DM patients capturing comorbidities, demographics, disease duration, hypo details. Patients self-reported work, activity impairment, lifestyle impact. Patients were grouped based on hypo experience by 1. ever experienced vs. never, 2. mild vs. severe, 3. never needed medical attention vs. needed. Propensity score matching on gender, BMI, disease duration facilitated comparison between matched groups. p-values generated using Abadie-Imbens standard errors, and standardized mean differences &lt;10% in matching covariates were sought.
Results: Of 1662 patients, 861 (51.8%) never experienced hypos, 637 (38.3%) experienced mild and 164 (9.9%) severe hypos. Only 46 (2.8%) experienced a hypo needing medical help. Patients with hypos were more likely ‘sometimes/greatly’ affected in feelings about the future and freedom to eat/drink (both p&lt;=0.001), leisure activities (p&lt;0.05) and self-confidence (p=0.056) vs. patients with no hypos. Severe hypo patients were more likely ‘sometimes/greatly’ affected when traveling (p=0.019) and were more likely to be anxious (p=0.007) or depressed (p=0.064) vs. mild hypo patients. While analysis of hypos needing medical attention was limited due to low bases, patients needing medical attention were more likely to have depression (p=0.003), anxiety (p=0.053) and increased work absenteeism (p&lt;0.01).
Conclusion: While physicians report half of T1DM patients do not experience hypos, those who do are more impacted concerning lifestyle, confidence and outlook. More severe hypos translates to increased psychological manifestations. During the management of these patients, the broader implications of hypo experience should not be underestimated.

Disclosure
E.D. Sullivan: None. J. Kemp: None. J. Piercy: None. V. Higgins: None.
415-P: Detection of Vascular Endothelial Cell DNA in the Circulation Using Dual Amplification Refractory Mutation System PCR
Authors: KURODA AKIO , YAMADA MISUZU YAMASHITA , TAKASHI YUICHI , OHISHI MAMI , MORI HIROYASU , ISHIZU MASASHI , SUZUKI REIKO , YINHUA OTSUKA , TOMINAGA YUKARI , MATSUHISA MUNEHIDE 
Published: June 2019

Background: Vascular complication of type 1 diabetes is associated with multiple factors. However, biomarkers which directly reflect vascular complication have not been elucidated. We have developed a method to detect unmethylated status of pancreatic β cell specific CpG sequences of insulin gene from cell-free DNA (cfDNA) in the circulation. Transmembrane protein ROBO4 is highly expressed in vascular endothelial cells, and it has been reported that the CpG sites in the promoter region are specifically unmethylated.
Aim: To develop a novel PCR method to specifically detect unmethylated CpG sites of ROBO4 gene promoter region in serum cfDNA and to evaluate this method in the supernatant of vascular endothelial cell culture and serum of patients with type 1 diabetes.
Material and Methods: After bisulfite conversion of cfDNA extracted from human umbilical vein endothelial cells (HUVEC) and patient serum, unmethylated ROBO4 gene was detected by the dual Amplifications Refractory Mutation Systems PCR, which amplifies only if 4 CpG sites (-185, -144, -118 and -103bp of transcription start sites of ROBO4) are all unmetylated. These methods were applied to 83 patients with type 1 diabetes (duration 16.1±13.9 years) and clinical characteristics were compared.
Results: In HUVEC culture supernatant under constant and intermittent high glucose condition, the detection of ROBO4 gene copy number increased depending on the number of dead cells and cfDNA concentration. A positive correlation (p &lt;0.05) with the mean intima-media thickness (IMT) and MCV were observed for the ROBO4 copy numbers in patient serum cfDNA. According to the multiple regression analysis, unmethylated ROBO4 copy number (p &lt;0.001) and age (p &lt;0.001) were selected as the determinant factors of mean IMT.
Conclusion: Novel PCR method for ROBO4 could detect vascular endothelial cell injury and atherosclerosis quantitatively in patients with type 1 diabetes.

Disclosure
A. Kuroda: Speaker's Bureau; Self; Eli Lilly and Company, Novo Nordisk Inc., Sanofi. M.Y. Yamada: None. Y. Takashi: None. M. Ohishi: None. H. Mori: None. M. Ishizu: None. R. Suzuki: None. O. Yinhua: None. Y. Tominaga: None. M. Matsuhisa: Advisory Panel; Self; Eli Lilly and Company. Board Member; Self; Daiichi Sankyo Company, Limited. Research Support; Self; Astellas Pharma Inc., Boehringer Ingelheim Pharmaceuticals, Inc., Mitsubishi Tanabe Pharma Corporation. Speaker's Bureau; Self; Astellas Pharma Inc., Eli Lilly and Company, Mitsubishi Tanabe Pharma Corporation, Novartis Pharmaceuticals Corporation, Novo Nordisk Inc., Sanofi, Takeda Pharmaceutical Company Limited.

Funding
Japan Society for the Promotion of Science
417-P: Serum Ceramide Ratios Predict Cardiovascular Events in Patients with Type 2 Diabetes Independently from the Presence of Coronary Artery Disease
Authors: LEIHERER ANDREAS , MUENDLEIN AXEL , SAELY CHRISTOPH H. , LAAKSONEN REJO , LAAPERI MITJA , VONBANK ALEXANDER , LARCHER BARBARA , MADER ARTHUR , FRAUNBERGER PETER , DREXEL HEINZ 
Published: June 2019

The ceramide ratios Cer(d18:1/16:0)/Cer(d18:1/24:0), Cer(d18:1/18:0)/Cer(d18:1/24:0) and Cer(d18:1/24:1)/Cer(d18:1/24:0) have recently been reported to be associated with cardiovascular risk. Data on their power to predict cardiovascular events in patients with type 2 diabetes (T2DM) are sparse, and it is unknown whether they prospectively predict cardiovascular events independently from the presence of coronary artery disease (CAD) at baseline. These issues are addressed in the present study. We measured the above-mentioned serum ceramide ratios in a cohort of 894 patients in whom the presence of CAD was determined angiographically. Prospectively, we recorded cardiovascular events over a mean follow-up time of 9.2±3.2 years. At baseline, the ratios Cer(d18:1/16:0)/Cer(d18:1/24:0), Cer(d18:1/18:0)/Cer(d18:1/24:0) and Cer(d18:1/24:1)/Cer(d18:1/24:0) were significantly higher in T2DM patients (n=239) than in patients without T2DM (0.11 vs. 0.10, p=0.011; 0.46 vs. 0.39, p&lt;0.001; and 0.46 vs. 0.41, p&lt;0.001), but did not differ significantly between patients with CAD (n=491) and those without CAD. Prospectively, vascular events occurred in 110 (47%) of the patients with T2DM and in 212 (33%) of nondiabetic patients (p&lt;0.001). For the ratio Cer(d18:1/16:0)/Cer(d18:1/24:0) a significant association with cardiovascular events in T2DM patients could be demonstrated univariately (standardized HR 1.23 [1.07-1.41], p=0.003), and after adjustment for age, gender, BMI, smoking, LDL cholesterol, HDL cholesterol, hypertension, statin intake, and also the for the CAD status at baseline (standardized adjusted HR 1.28 [1.10-1.50], p=0.002). We conclude that ceramide ratios have the potential to predict cardiovascular events in patients with T2DM, independent from their baseline CAD status. Further research addressing the selection of optimal ceramide species for risk prediction appears warranted.

Disclosure
A. Leiherer: None. A. Muendlein: None. C.H. Saely: None. R. Laaksonen: None. M. Laaperi: None. A. Vonbank: None. B. Larcher: None. A. Mader: None. P. Fraunberger: None. H. Drexel: None.
435-P: Elevated One-Hour Post-Challenge Glucose Levels Associated with Increased Arterial Stiffness
Authors: OKADA SHUICHI , OKADA JUNICHI , YAMADA EIJIRO , SAITO TSUGUMICHI , YAMADA MASANOBU 
Published: June 2019

We reported a positive correlation between brachial-ankle pulse wave velocity (baPWV) and one-hour post-challenge glucose (1-h PG). Furthermore, the subpopulation defined by 1-hour PG beyond 183 mg/dL (corresponded to Impaired glucose tolerance range of 2-h PG) in normal glucose tolerant (NGT) subjects. These findings suggested that if NGT subjects convert to higher 1-h PG levels from a normal 1-h PG range they will develop arterial stiffness. To address this issue, we initiated a clinical study that included 40 NGT subjects (23 men and 17 women, mean age 60.9 ±9.7 years), with a comprehensive medical check-up was performed on each subject at Kan-etsu Chuo Hospital every year. In addition, over the 9-year period these individuals were annually assessed by a 75-g oral glucose tolerance test (OGTT) and for atrial stiffness by baPWV. Based on the 75-g OGTT, NGT subjects alone were selected according to the 2006 WHO criteria. NGT subjects in this study were identified as individuals having a normal range of all measured parameters. In this population, there was no significant correlation between baPVW and all measured parameters. One-h post challenge glucose (1-h PG) in 28 subjects was below 154 mg/dL and their baPWV was not changed (1266.4 ±125.42 cm/sec from 1243.62 ±108.1) after nine years. On the other hand, 1-h PG in the rest of 12 subjects was significantly increased to 160.33 ±4.73 from 124.67 ±20.13 and their baPVW was also significantly elevated to 1489.33 ±41.05 from 1255.01 ±64.08 after nine years. We found that rapid blood glucose change in NGT could be a risk factor for arterial stiffness and we would like to point out the possibility for physicians to select high-risk subjects by 75g-OGTT with the evaluation of 1h-PG. Taken together, we found that rapid blood glucose change could be a risk factor for arterial stiffness.

Disclosure
S. Okada: None. J. Okada: None. E. Yamada: None. T. Saito: None. M. Yamada: None.
44-OR: Human Pseudo Islets Reveal Differential Effects of Gq Signaling in ß Cells in Low and High Glucose
Authors: WALKER JOHN T. , HALIYUR RACHANA , ARAMANDLA RADHIKA , POFFENBERGER GREG , NELSON HEATHER A. , LUCHSINGER JOSEPH , WANG PENG , GARCIA-OCAÑA ADOLFO , BRISSOVA MARCELA , POWERS ALVIN C. 
Published: June 2019

Efforts to advance our understanding of human islet biology are hindered by a paucity of approaches to effectively manipulate gene expression in human islets. To address this, we developed a pseudoislet system of human islet dispersion and reaggregation via modified hanging drop with 2500 cells/drop to generate 150-200 μm diameter pseudoislets (n=9 normal donors; 26-73 years). Pseudoislet morphology, dithizone uptake, and expression of markers of α and/or β cell identity (PDX1, NKX6.1, ARX, MAFB, NKX2.2, and PAX6) were similar to native islets; in paired comparisons from the same donor, pseudoislets had slightly fewer β cells and more α cells (53% β, 44% α, 3% δ cells) than native islets (62% β, 35% α, 3% δ cells; p&lt;0.05 β and α cells). In perifusion, pseudoislets were similar to native islets in biphasic glucose-stimulated and cAMP-potentiated insulin secretion as well as in epinephrine and low glucose stimulation of and high glucose inhibition of glucagon release. Adenoviral-transduced dispersed human islet cells (&gt;90% β cell transduction) formed functioning pseudoislets similar to untransduced controls. Using this approach, we virally expressed hM3Dq, a Gq-coupled designer receptor exclusively activated by a designer drug (DREADD), which selectively responds to the otherwise inert ligand clozapine-n-oxide (CNO) and signals through PLC/IP3. In low glucose (2mM G + 10μM CNO), hM3Dq pseudoislets secreted more insulin than control mCherry pseudoislets (19.2 vs. 1.0 ng/100IEQ/hr; p&lt;0.0001). In contrast, hM3Dq and control pseudoislets had similar insulin secretion in high glucose (11mM G + 10μM CNO; 24.8 vs. 23.2 ng/100IEQ/hr; p&gt;0.05), indicating that activation of Gq signaling does not potentiate insulin secretion in high glucose. These data demonstrate how manipulation of gene expression in pseudoislets can provide insight into human islet biology and suggest that activation of Gq signaling in β cells elicits robust insulin secretion that appears to be uncoupled from glucose metabolism.

Disclosure
J.T. Walker: None. R. Haliyur: None. R. Aramandla: None. G. Poffenberger: None. H.A. Nelson: None. J. Luchsinger: None. P. Wang: None. A. Garcia-Ocaña: None. M. Brissova: None. A.C. Powers: None.
442-P: Excess Burden of Adverse In-Hospital Outcomes in Patients with Diabetes Hospitalized for Stroke
Authors: DAURIZ MARCO , TREGNAGHI ELENA , SANTI LORENZA , LUCIANER TIZIANO , ALTOMARI ANNA , RINALDI ELISABETTA , TARDIVO STEFANO , BOVO CHIARA , BONORA ENZO 
Published: June 2019

Cerebrovascular accidents (CVA) represent a major complication in diabetes (DM). Real-life evidence as to whether modern management of CVA and DM have softened this relationship is currently limited. We assessed the prevalence of DM, previously known or newly-diagnosed, in all patients (N=542, males 51.5%) admitted for CVA at the Stroke Unit (SU) of Verona University Hospital from 1/1/2015 to 12/31/2016. DM was ascertained by previous diagnosis, glucose-lowering therapy at admission/discharge or admittance plasma glucose (PG) ≥11.1 mmol/L. Prevalence of DM was 21.03% (78.1% known-DM; 21.9% new-DM). In-hospital death rate was 10.5%. Compared to non-DM, patients with DM showed an increased risk of death (15.8 vs. 9.1%; OR 1.87 95% CI, 1.03-3.41) and complications (48.2 vs. 33.3%; 1.87, 1.22-2.86) with similar duration of hospitalization (mean±SEM, 9.14±1.06 vs. 8.80±0.39 days, p=0.72). All deaths occurred in the SU. The “survivors” with DM transferred to non-intensive ward had an out-of-SU hospital stay twice as longer than non-DM (2.32±1.02 vs. 0.98±0.19 days, p=0.038). After multivariable adjustment, DM remained predictor of complications (adj-OR 1.87, 1.22-2.86) but not mortality (1.79, 0.92-3.46). Patients in the highest PG quartile (≥6.55 mmol/L) displayed the highest risk of death (7.89, 2.73-22.79; PG&lt;4.77 mmol/L, ref.) and complications (2.30, 1.24-4.23), independent of diabetes status, glucose-lowering medications, CVA treatment and established CVA risk factors. Individuals in the older age tertile (≥81 years) were at increased risk of death (3.25, 1.40-7.54; age &lt;72 years, ref.), while risk of infectious/cardiorespiratory complications was higher at younger age (3.13, 1.42-6.9). No difference was observed in new-DM vs. known-DM.
In conclusion, these data highlight that DM frequently occurs in patients admitted for CVA and adds an excess burden of adverse clinical outcomes that urgently calls for strategies to anticipate DM diagnosis in high-risk individuals.

Disclosure
M. Dauriz: None. E. Tregnaghi: None. L. Santi: None. T. Lucianer: None. A. Altomari: None. E. Rinaldi: None. S. Tardivo: None. C. Bovo: None. E. Bonora: None.
447-P: Low Muscle Mass Is Associated with Carotid Atherosclerosis in Korean Men with Type 2 Diabetes
Authors: NAM MOON-SUK , SEO DA HEA , JUNG MIHYE , AHN SEONG HEE , HONG SEONGBIN , LEE YONG-HO , CHOI YOUNGJU , HUH BYOUNG WOOK , HUH KAP BUM , KIM SO HUN 
Published: June 2019

Background: Sarcopenia, an age-related decline in skeletal muscle mass, leads to metabolic and vascular abnormalities. However, little is known regarding the independent relationship between skeletal muscle mass and atherosclerosis in patients with type 2 diabetes mellitus (T2DM). The purpose of this study was to evaluate the association of skeletal muscle mass with markers of carotid atherosclerosis, carotid intima-media thickness (CIMT) and carotid artery plaque, in men and women with T2DM.
Methods: In this cross-sectional study, a total of 8,918 patients (4,520 men and 4,398 women) with T2DM were recruited from the outpatient clinic of Huh’s Diabetes Center from 2003 to 2016. Skeletal muscle mass was estimated from bioimpedance analysis measurements and skeletal muscle mass index (SMI, %) was defined as skeletal muscle mass (kg)/total body weight (kg) × 100. Carotid ultrasonography was performed to measure mean CIMT of both common carotid arteries. Carotid artery plaque was defined as a focal structure protruding into the lumen of the vessel of ≥50% than the surrounding area.
Results: In both men and women, the presence of carotid artery plaque was higher with decreasing SMI quartiles. In men, this association remained significant after adjustment for additional risk factors (ptrend &lt;0.001). Odds ratio for having carotid artery plaque was 1.76 (95% confidence interval [CI] 1.34-2.33; p &lt;0.001) in men with lowest SMI quartile compared with highest quartile. However, in women, the association was attenuated after adjustment for additional risk factors. There was no significant association between SMI quartiles and CIMT in both men and women.
Conclusion: Low muscle mass is associated with the presence of carotid artery plaque in men with T2DM.

Disclosure
M. Nam: None. D. Seo: None. M. Jung: None. S. Ahn: None. S. Hong: None. Y. Lee: None. Y. Choi: None. B. Huh: None. K. Huh: None. S. Kim: None.

Funding
National Research Foundation of Korea (2017R1D-1A1B03034581)
448-P: Predictors and Their Impact on Coronary Artery Disease (CAD) According to Glucose Tolerance Status (GTS) and Prior CAD: Historical Cohort Study in Japan
Authors: KITAZAWA MASARU , FUJIHARA KAZUYA , OSAWA TAEKO , YAMAMOTO MASAHIKO , HARADA MAYUKO , KANEKO MASANORI , MATSUBAYASHI YASUHIRO , YAMADA TAKAHO , YAMANAKA NAUTA , SEIDA HIROYASU , OGAWA WATARU , SONE HIROHITO 
Published: June 2019

Although GTS, prior CAD and other traditional risk factors independently affect incidence of subsequent CAD, their impact in the same cohort has been scantly studied. We analyzed a nationwide claims-based database of 138,162 men aged 18-72 y in 2008-14. Participants were classified as normal glucose tolerance (NGT, n=78,230), prediabetes (PreDM, n=45,610) or diabetes mellitus (DM, n=14,322) based on blood tests and prescriptions and with prior (CAD+) or without prior CAD (CAD-) based on ICD-10 codes and questionnaires. Among CAD-, management of traditional risks differed from those with and without CAD events, while such differences were weaker in preDM and DM with CAD+. Cox regression model showed that PreDM and DM confer approximately 1.2- and 2.8-fold excess risk of CAD, respectively, compared with CVD- with NGT. CAD+ confers approximately a 5- to 8-fold increased risk. Most traditional risks were independently associated with subsequent CAD in the CAD- group regardless of GTS. Conversely, in the CAD+ group, their impact was weakened and only HDL-C was a significant risk factor for future CAD in those with DM and CAD+ (Table). Thus, the impact of known risks on subsequent CAD differs markedly according to GTS and CAD+. Those with CAD+ and glucose abnormality, especially DM, need treatment residual risk factors as well as traditional risk factors.

Disclosure
M. Kitazawa: None. K. Fujihara: None. T. Osawa: None. M. Yamamoto: None. M. Harada: None. M. Kaneko: None. Y. Matsubayashi: None. T. Yamada: None. N. Yamanaka: None. H. Seida: None. W. Ogawa: Consultant; Self; Abbott. Research Support; Self; Astellas Pharma Inc., AstraZeneca, Boehringer Ingelheim International GmbH, Daiichi Sankyo Company, Limited, Mitsubishi Tanabe Pharma Corporation, Takeda Pharmaceutical Company Limited. Speaker's Bureau; Self; Lilly Diabetes, Novo Nordisk Inc., Ono Pharmaceutical Co., Ltd., Sanofi, Sumitomo Dainippon Pharma Co., Ltd. H. Sone: Research Support; Self; Astellas Pharma Inc., Boehringer Ingelheim Pharmaceuticals, Inc., Daiichi Sankyo Company, Limited, Kowa Pharmaceutical Europe Co. Ltd., Kyowa Hakko Kirin Co., Ltd., Novo Nordisk Inc., Ono Pharmaceutical Co., Ltd., Taisho Pharmaceutical Co., Ltd., Takeda Pharmaceutical Company Limited, Teijin Pharma Limited.
458-P: 1H-MRS Lipid Spectra of Interventricular Septum (SEP): A Novel Marker of Cardiovascular (CV) Events in Hyperglycemic (HG) Patients
Authors: CODELLA ROBERTO , LEO GIOVANNI DI , ZANARDO MORENO , SCHIAFFINO SIMONE , FABIANO SALVATORE DIONIGI , MONTI C. B. , CODARI MARINA , LUZI LIVIO , SARDANELLI FRANCESCO 
Published: June 2019

Proton magnetic resonance spectroscopy (1H-MRS) can detect and quantify lipid accumulation in specific myocardial or peri-myocardial districts. Thirty-three patients (20M/13F; BMI 26±4 kg/m2; 64±10 years) with suspect of CV diseases underwent 1.5-T 1H-MRS using a water-suppressed chemical-shift imaging sequence to quantify the lipid profile of SEP, epicardial (EAT), pericardial (PAT), and subcutaneous (SAT) adipose tissues. The integral of the lipid peaks at 0.9, 1.3, 2.0, 5.3 ppm was measured as percentage over the total amount of lipids (Table). A subgroup of 15 subjects were identified as HG (12 impaired-fasting-glucose and 3 diabetics: 121±26 mg/dL). Bulk methylene (1.3 ppm) of SEP was higher in HG vs. other patients (P=0.047). In HG patients, SEP was positively correlated to glucose, visceral fat, C-reactive protein (Spearman ρ&gt;0.63, P&lt;0.018); EAT was positively correlated to visceral fat, age, body weight, and inversely to muscular-, fat free-, bone mass (Pearson ρ&lt;|0.53|, P&gt;0.039). In all subjects, the main lipid peaks correlated with metabolic parameters.1H-MRS allowed to measure lipid peaks in different adipose compartments with cardiometabolic relevance. SEP resulted a myocardial site associated with biomarkers of secondary heart events in pre/diabetic patients at higher risk of CV episodes. High SEP fat may be proposed as a marker of future CV events.

Disclosure
R. Codella: None. G. Di Leo: None. M. Zanardo: None. S. Schiaffino: Speaker's Bureau; Self; General Electric. S.D. Fabiano: None. C.B. Monti: None. M. Codari: None. L. Luzi: Consultant; Self; McKinsey & Company. Research Support; Self; Allergan, Gelesis, SunStar Inc. Speaker's Bureau; Self; A. Menarini Diagnostics, AstraZeneca, Eli Lilly and Company, GlaxoSmithKline plc., Menarini Group, Novartis AG, Novo Nordisk Inc., Sunstar Foundation. F. Sardanelli: None.
459-P: Risk for Type 2 Diabetes and Cardiovascular Health in Children Treated with Second-Generation Antipsychotics
Authors: HENDERSON AMANDA M. , ISLAM NAZRUL , SANDOR GEORGE GABOR , PANAGIOTOPOULOS CONSTADINA , DEVLIN ANGELA M. 
Published: June 2019

Background: Second-generation antipsychotics (SGAs) are used to treat mental illness in children but have side effects including weight gain, dyslipidemia, hypertension, and risk for type 2 diabetes. These side effects are well-known risk factors for cardiovascular disease. However, little is known about the cardiovascular health of SGA-treated children.
Methods: Cross-sectional study of children (aged 6-18 years) with mental illness that were SGA-treated (n=47) or SGA-naïve (n=37), and control children (n=83, no mental illness). Anthropometrics and a fasting blood sample were collected. Subclinical indicators of atherosclerosis were assessed. Central pulse-wave velocity (PWV) by standard M-mode echocardiography and Doppler tracing, an indicator of arterial stiffness, and carotid intima-media thickness (cIMT) were assessed.
Results: SGA-treated children had greater BMI z-scores (p&lt;0.001) and higher (p&lt;0.001) prevalence of overweight/obesity (BMI ≥85th percentile for age and sex) than SGA-naïve and control children. SGA-treated children had higher fasting plasma insulin (p=0.016) and 21.7% had hyperinsulinemia (fasting insulin ≥100pmol/L) compared to 12.9% of SGA-naïve children. No differences in fasting glucose or circulating lipids were observed. Hypertension was observed in 14.9% of SGA-treated children, compared to 5.4% of SGA-naïve and 6.0% of control children. SGA-treated (p=0.002) and SGA-naive children (p&lt;0.001) had higher PWV compared to controls (adjusted for age, sex, BMI, systolic blood pressure). No effect of SGAs or mental health diagnosis on cIMT was observed.
Conclusion: Children with mental illness have greater arterial stiffness than control children.

Disclosure
A.M. Henderson: None. N. Islam: None. G.G. Sandor: None. C. Panagiotopoulos: Advisory Panel; Self; Dexcom, Inc. A.M. Devlin: None.

Funding
British Columbia Mental Health & Substance Use Services